Overview
Lobbying Costs
350,000€
Financial year: Jan 2018 - Dec 2018
Lobbyists (Full time equivalent)
1.5 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
7
Lobbying Costs over the years
-
Info
Novo Nordisk A/S
EU Transparency Register
29570313329-11 First registered on 13 Mar 2010
Goals / Remit
Novo Nordisk is a global healthcare company with over 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 40000 employees in 75 countries. It markets products and services that make a significant difference to patients, the medical profession and society in 190 countries.
Novo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line). This commitment is demonstrated through its values and its environmental and social responsibility policies.
The Novo Nordisk Foundation is a non-profit institution, whose formal purpose is to provide a stable basis for its company's operations and to make contributions to scientific, humanitarian and social progress.
Novo A/S is an unlisted Danish public limited liability company, owned by the Novo Nordisk Foundation and established to manage the Foundation's funds and to invest actively in other companies.
All A and B shares in Novo Nordisk A/S, previously held by the Novo Nordisk Foundation, were transferred to Novo A/S on 31 December 1999. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).Main EU files targeted
EU Pharmaceutical related legislation (in the fields of public health, research and technology, environment,
enterprise and trade).
IMIAddress
Head Office
Novo Nordisk A/S
Novo Allé, 1
Bagsværd 2880
DENMARKEU Office
Novo Nordisk Pharma nv
Boulevard International 55
Anderlecht 1070
BELGIUM -
People
Total lobbyists declared
3
Employment time Lobbyists 50% 3 Lobbyists (Full time equivalent)
1.5
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 10 Apr 2019
Name Start date End Date Matthew Thomas Vincent CLAY 27 Oct 2023 25 Oct 2024 Alexander Von Wildenrath LØVGREEN 08 Apr 2024 08 Apr 2026 Ms Helen Oberg 12 Apr 2023 26 Apr 2024 Mr Christian JUUL NYHUS 16 Feb 2023 16 Feb 2024 Mr Alexander VON WILDENRATH LØVGREEN 16 Feb 2023 16 Feb 2024 Mr Matthew CLAY 07 Jun 2022 07 Jun 2023 Mr Vincent CLAY 07 Jun 2022 27 Jun 2022 Jeppe Torp VESTENTOFT 03 Dec 2019 01 Aug 2020 Ms Victoria Breck 30 Nov 2019 28 Nov 2020 Ms Ane Sofie Böhm Nielsen 23 Sep 2014 19 Sep 2015 Mr Troels Anders RYE-ANDERSEN 08 Aug 2014 06 Aug 2015 Mr Morten Frank Pedersen 19 Sep 2013 18 Sep 2014 Ms Engelbertha Maria Rouweler 17 Sep 2013 14 Mar 2014 Mr Neil David Causey 17 Sep 2013 14 Sep 2014 Mr Troels Anders RYE-ANDERSEN 07 Jun 2013 06 Jun 2014 Mr Troels Anders RYE-ANDERSEN 16 Jan 2012 08 Feb 2013 Complementary Information
None declared
Person in charge of EU relations
Mr Jeppe Torp Vestentoft (Policy Lead - Head of EU Government Affairs)
Person with legal responsibility
Mr Lars Fruergaard Jørgensen (CEO)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Novo Nordisk is member of:
EFPIA - European Federation of Pharmaceutical Industries and Associations
EuropaBio - European Association for Bioindustries
Danish Chamber of Commerce
Eucomed
IFPMA - International Federation of Pharmaceutical Manufacturers & AssociationsMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2018 - Dec 2018
Lobbying costs for closed financial year
350,000€
Other financial info
This estimate (based on a proportion of member association fees and a percentage of covered staff salaries) has been done according to the Transparency Register Implementing Guidelines of 5 October 2015 and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
None
Other activities
Novo Nordisk's goals with its involvement with EU institutions are:
- to improve conditions for prevention, treatment and care in Europe to address unmet needs
- to support the voice of people living with or at risk of
developing diabetes
- to increase Europe´s competitiveness as a location for Research and Development- Meetings
Meetings
7 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 17 Jan 2024 Location Davos Subject Meeting with Ms Camilla Sylvest, Executive Vice-President. Cabinet Cabinet of Commissioner Stella Kyriakides Attending - Giorgios Rossides (Cabinet member)
- Stella Kyriakides (Commissioner)
-
Date 30 Mar 2023 Location Brussels, Belgium Subject The discussion will be focused on the up-coming legislation on plants produced by certain genomic techniques, and the revision of plant-proteins. Cabinet Cabinet of Commissioner Janusz Wojciechowski Portfolio Agriculture Attending - Jorge Pinto Antunes (Cabinet member)
Other Lobbyists -
Date 06 Dec 2022 Location Brussels Subject Revision of the EU pharmaceutical legislation. Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Pierre-Arnaud Proux (Cabinet member)
-
Date 16 Sep 2021 Location Brussels Subject Discussion with EFPIA and Novo Nordisk on how the pharmaceutical industry could contribute to the EU's agenda for open strategic autonomy and the renewed industrial strategy and on the green transformations of the pharmaceutical sector. DG Internal Market, Industry, Entrepreneurship and SMEs Attending - Kerstin Jorna (Director-General)
-
Date 16 Jun 2021 Location online Subject Supply chains for medicines Cabinet Cabinet of Vice-President Margaritis Schinas Portfolio Promoting the European Way of Life Attending - Maria Luisa Llano Cardenal (Cabinet member)
- Margaritis Schinas (Vice-President)
Other Lobbyists - European Healthcare Distribution Association
- European Patients' Forum (EPF)
- Bureau Européen des Unions de Consommateurs
- Medichem, S.A.
- MEDICINES FOR EUROPE
- Leuphana Universität Lüneburg
- Fresenius Kabi Deutschland GmbH
- Pfizer Inc.
- The European Association of Hospital Pharmacists
- European Chemical Industry Council
- Teva Pharmaceuticals Europe BV
- SANOFI
- Phamaceutical Group of the European Union
- European Federation of Pharmaceutical Industries and Associations
-
Date 21 May 2021 Location Copenhagen Subject Industrial Strategy Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Margrethe Vestager (Executive Vice-President)
Other Lobbyists -
Date 25 Jan 2021 Location Brussels Subject Commission’s priorities for digital and industrial policy in 2021 Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Christiane Canenbley (Cabinet member)
- Michele Piergiovanni (Cabinet member)
Other Lobbyists
- Meetings